Welcome to our dedicated page for ICU Medical news (Ticker: $ICUI), a resource for investors and traders seeking the latest updates and insights on ICU Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ICU Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ICU Medical's position in the market.
ICU Medical, Inc. announced its First Quarter 2024 Results with revenue of $566.7 million, a slight decrease from the previous year. The GAAP gross profit was $185.2 million, with a net loss of $(39.5) million. Adjusted diluted earnings per share were $0.96, and Adjusted EBITDA was $78.8 million. Revenues by product line showed fluctuations, with Vital Care including revenue from a Pfizer contract. CEO Vivek Jain stated that the results were as expected.